Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis

NCT01904409 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

420

Enrollment

INDUSTRY

Sponsor class

Conditions

Liver Cirrhosis

Interventions

DRUG: Placebo
DRUG: Rifaximin SSD 40 mg IR tablet
DRUG: Rifaximin SSD 80 mg IR tablet
DRUG: Rifaximin SSD 40 mg SER tablet
DRUG: Rifaximin SSD 80 mg SER tablet
DRUG: Rifaximin SSD 80mgIR/80mgSER tablet

Sponsor

Bausch Health Americas, Inc.